Showing results (641-650 of 677) with videos related to

Sort By:
Pageof 68
Pediatrics|October 12, 2011
Strategies for implementing screening for critical congenital heart diseaseAlex R Kemper, William T Mahle, Gerard R Martin, et al.
Reproduction (Cambridge, England)|April 10, 2003
Effect of treatment with the selective oestrogen receptor modulator LY117018-HCl on pituitary sensitivity to GnRH and subsequent ovulationG Hernández, J G Hernández-Jiménez, P Guelmes, et al.
Medical and Pediatric Oncology|January 1, 1979
A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemiaP H Wiernik, O J Glidewell, H C Hoagland, et al.
Plos Medicine|February 29, 2020
An adaptable implementation package targeting evidence-based indicators in primary care: A pragmatic cluster-randomised evaluationThomas A Willis, Michelle Collinson, Liz Glidewell, et al.
Cell Stem Cell|March 20, 2026
Species-specific chromatin architecture and neurogenesis mediated by a human enhancerFederica Mosti, Jing Liu, Katie Lam, et al.
The Journal of Pediatrics|September 19, 2025
Timing of Critical Congenital Heart Defect Detection: A Multisite Population-Based StudyShannon E Moss, Elizabeth C Ailes, Karrie F Downing, et al.
Endocrinology|August 23, 2014
KISS1R signals independently of Gαq/11 and triggers LH secretion via the β-arrestin pathway in the male mouseMaryse Ahow, Le Min, Macarena Pampillo, et al.
Implementation Science : IS|December 14, 2016
A multidimensional approach to assessing intervention fidelity in a process evaluation of audit and feedback interventions to reduce unnecessary blood transfusions: a study protocolFabiana Lorencatto, Natalie J Gould, Stephen A McIntyre, et al.
Neurogenetics|October 16, 2008
Chromosomal microarray mapping suggests a role for BSX and Neurogranin in neurocognitive and behavioral defects in the 11q terminal deletion disorder (Jacobsen syndrome)C D Coldren, Z Lai, P Shragg, et al.
Medical and Pediatric Oncology|January 1, 1975
The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myelomaJ Cuttner, L R Wasserman, G Martz, et al.
Pageof 68